Quick Answer
Nurix Therapeutics, Inc. reported Diluted EPS of $3.05 per share (loss) for fiscal year 2025.
Nurix Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$3.05 | -5.9% |
| 2024 | -$2.88 | -8.7% |
| 2023 | -$2.65 | +28.6% |
| 2022 | -$3.71 | -35.9% |
| 2021 | -$2.73 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| August 31, 2025 | -$1.03 | -53.7% | -98.1% |
| May 31, 2025 | -$0.52 | +26.8% | +22.4% |
| February 28, 2025 | -$0.67 | +11.8% | +0.0% |
| August 31, 2024 | -$0.67 | +1.5% | +5.6% |
| May 31, 2024 | -$0.71 | -57.8% | +6.6% |
| February 29, 2024 | -$0.76 | -1.3% | -11.8% |
| August 31, 2023 | -$0.68 | +24.4% | -51.1% |
| May 31, 2023 | -$0.45 | +55.4% | +40.0% |
- Nurix Therapeutics, Inc. showed a decrease of -5.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Nurix Therapeutics, Inc.’s diluted eps has declined by 11.7% (from $2.73 per share (loss) to $3.05 per share (loss)).
- The most recent figure is from Nurix Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on January 28, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: